BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News The Peptide Boom Is Getting Out of Hand The Atlantic The Peptide Craze Ground Truths BPC 157 Banned: Key Facts on the Latest FDA Decision